Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ETNEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financ ...

Core Viewpoint - Anavex Life Sciences is focused on developing targeted therapeutics for central nervous system (CNS) diseases, particularly Alzheimer's disease, by enhancing the body's natural defense mechanisms and restoring cellular homeostasis through innovative treatments [3][4]. Company Overview - Anavex Life Sciences is a public company dedicated to the discovery and development of therapeutics aimed at CNS treatment [2]. - The company emphasizes a proactive approach to addressing complex diseases by targeting upstream processes rather than fixing downstream issues [4]. Product Focus - The lead asset of Anavex, blarcamesine, is a once-daily oral small molecule designed to enhance autophagy through sigma-1 activation [4]. - The impairment of autophagy processes is identified as a precursor to neurodegenerative processes in Alzheimer's disease, indicating the potential effectiveness of blarcamesine in this area [5].

Anavex Life Sciences (NasdaqGS:AVXL) FY Conference January 14, 2026 07:30 PM ET Company ParticipantsColette Van Buchem - Investment Banking AssociateChristopher Missling - President and CEOColette Van BuchemGood afternoon and welcome, everyone. I'm Colette van Buchem, an associate at JPMorgan on the healthcare team in New York. Today it's my pleasure to introduce Anavex Life Sciences. With me on stage, we have Christopher Missling, President and CEO. Christopher, I'll pass it over to you. Thank you.Christop ...

Core Insights - Anavex Life Sciences Corp. is participating in ACCESS-AD, a European initiative aimed at enhancing the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease over a five-year period, funded by the European Commission's Innovative Health Initiative [1][2] Group 1: Alzheimer's Disease Management - ACCESS-AD is launched at a critical time as the prevalence of Alzheimer's disease in Europe is projected to exceed 19 million by 2050, highlighting the urgent need for scalable and accessible therapeutic options [2] - Recent approvals of antibody-based disease-modifying therapies (DMTs) have expanded treatment options, but health systems still face significant challenges in diagnosis, patient stratification, imaging capacity, and ongoing monitoring [2] Group 2: Precision Medicine and Blarcamesine - Blarcamesine, an investigational small-molecule therapy, will be evaluated within ACCESS-AD to target autophagy through SIGMAR1 activation, aiming to restore cellular function and slow neurodegenerative processes in Alzheimer's disease [3][5] - The integration of blarcamesine into ACCESS-AD's framework will facilitate the generation of predictive clinical insights using harmonized imaging, biomarker, and digital datasets [5] Group 3: Clinical Framework and Innovation - ACCESS-AD is establishing a coordinated clinical framework that incorporates advanced neuroimaging, blood-based biomarkers, digital measures, and AI-driven decision support to streamline patient pathways across Europe [4] - The initiative aims to support early detection, personalized treatment choices, and the safe implementation of emerging therapies [4] Group 4: Company Overview - Anavex Life Sciences Corp. is focused on developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, with its lead drug candidate, ANAVEX2-73 (blarcamesine), having completed multiple clinical trials [9] - The company is committed to precision medicine approaches that incorporate clinical data, genomic markers, and digital endpoints to enhance treatment efficacy [5][9]

Company Overview - Anavex Life Sciences Corp. is a clinical-stage biotech company focused on developing targeted therapies for neurodegenerative and CNS disorders, including Alzheimer's and Parkinson's disease [3]. Allegations and Stock Impact - Anavex is under investigation for potential violations of federal securities laws due to allegations of providing misleading business information to investors [1]. - On November 14, 2025, Anavex announced an unfavorable preliminary opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its marketing application for blarcamesine, leading to a significant stock price drop of $2.05 per share, or 35.94%, closing at $3.65 per share on the same day [4].

Core Insights - Anavex Life Sciences Corp. has appointed Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology, to enhance its focus on developing treatments for CNS disorders [1][3] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company dedicated to innovative treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and Rett syndrome [4] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials, including Phase 2a and Phase 2b/3 for Alzheimer's disease, and shows potential in treating various CNS disorders [4] Dr. Wolfgang Liedtke's Background - Dr. Liedtke is a board-certified neurologist with over 25 years of experience in CNS diseases and has led significant clinical trials, including a CNS trial with over 11,000 patients [2] - His previous role was Chair of Neurology at Regeneron, where he integrated discovery into 45 clinical trials, including 14 Phase 3 studies [2] - Dr. Liedtke has authored over 160 peer-reviewed publications and holds a current h-index of 82, indicating his significant contributions to the field [2] Strategic Importance of Appointment - The appointment of Dr. Liedtke is seen as crucial for advancing Anavex's mission to improve patient outcomes through innovative, patient-centered treatments [3] - Dr. Liedtke emphasizes the unmet global need in treating Alzheimer's and Parkinson's diseases, aligning with Anavex's focus on precision medicine [3]

Core Insights - Anavex Life Sciences Corp. has appointed Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology, to enhance its focus on developing treatments for CNS disorders [1][3]. Group 1: Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company dedicated to innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS disorders [4]. - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials, including Phase 2a and Phase 2b/3 for Alzheimer's disease, and shows potential for treating various CNS disorders [4]. Group 2: Dr. Wolfgang Liedtke's Background - Dr. Liedtke is a board-certified neurologist with over 25 years of experience in CNS diseases and has led significant clinical trials, including a CNS trial with over 11,000 patients [2]. - His previous role was Chair of Neurology at Regeneron, where he integrated discovery into 45 clinical trials, including 14 Phase 3 studies [2]. - Dr. Liedtke has authored over 160 peer-reviewed publications and holds a current h-index of 82, indicating his significant contributions to the field [2]. Group 3: Strategic Importance of Appointment - The appointment of Dr. Liedtke is seen as crucial for advancing Anavex's mission to improve patient outcomes through personalized treatments [3]. - Dr. Liedtke emphasizes the unmet global need in treating Alzheimer's and Parkinson's diseases, aligning with Anavex's innovative approach to precision medicine [3].

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Anavex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Novem ...

Core Insights - Anavex Life Sciences Corp. has received an invitation from the U.S. FDA to present its clinical trial results for Alzheimer's disease, indicating the FDA's interest in the company's development efforts [1][3] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS disorders [1][6] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [6] FDA Interaction - During a Type C meeting, the FDA expressed a collaborative approach towards Anavex's development plans and discussed potential pathways for submitting a New Drug Application (NDA) for Alzheimer's disease [2][3] - Anavex plans to submit existing data from the Phase IIb/III ANAVEX2-73-AD-004 program as requested by the FDA to facilitate the evaluation of its Alzheimer's disease program [3] Drug Profile - Blarcamesine is noted for its oral administration convenience and has not shown significant safety concerns in clinical trials, including the absence of amyloid-related imaging abnormalities (ARIA) [2] - The drug is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease progression [6] Alzheimer's Disease Context - Alzheimer's disease accounts for 60-80% of all dementia cases globally, highlighting a significant unmet need for new treatment options to slow disease progression and reduce societal burden [5]

Core Viewpoint - Anavex Life Sciences Corp. has requested the European Medicines Agency to re-examine its opinion on blarcamesine for treating early Alzheimer's disease, highlighting the significant unmet need for innovative treatment options in this area [1][2][4]. Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS disorders [1][5]. - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [5]. Regulatory Engagement - Anavex is collaborating closely with the EMA during the re-examination process, which will involve a new evaluation by different rapporteurs and consultation with a Scientific Advisory Group for independent recommendations [2][3]. Alzheimer's Disease Context - Alzheimer's disease accounts for 60-80% of all dementia cases globally, representing a significant challenge for patients and caregivers, with a pressing need for new treatment options to slow disease progression [4].